1. Scilex announces Dream Bowl 2026 Meme Coin distribution starting December 24, 2025. 2. Eligible shareholders can claim tokens through a designated process. 3. Scilex focuses on developing non-opioid pain management products. 4. Company has several FDA-approved products and ongoing clinical trials. 5. Forward-looking statements highlight potential risks and uncertainties.
FAQ
Why Bullish?
The introduction of a Meme Coin may attract speculative interest, boosting SCLX's visibility. Past examples like Dogecoin show how digital assets can influence parent companies' stock prices.
How important is it?
The novelty of the token distribution could engage current shareholders and attract new investors, though actual revenue implications are uncertain.
Why Short Term?
There will be immediate attention due to the upcoming distribution, but long-term effects depend on market acceptance.
Scilex Holding Company Announces Dream Bowl 2026 Meme Coin Claim Process
PALO ALTO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX) has confirmed the claim process for the Dream Bowl 2026 Meme Coin, which will be available starting December 24, 2025. This innovative distribution is powered by Datavault AI's advanced blockchain technology, integrating sports, digital assets, and unique shareholder benefits.
Claim Process Details
Eligible shareholders of record as of November 25, 2025, can claim their allotted Dream Bowl 2026 Meme Coins beginning December 24, 2025. The tokens can be claimed through a designated process outlined on www.dreambowlcoin.com.
- Event Date: December 24, 2025
- Eligibility: Shareholders on record by November 25, 2025
- Claim Instructions: Available at www.dreambowlcoin.com
About Scilex Holding Company (SCLX)
Scilex is focused on acquiring, developing, and commercializing non-opioid pain management therapeutics to address acute and chronic pain along with various neurodegenerative and cardiometabolic diseases. With a commitment to improving patient outcomes, the Company targets significant market opportunities in pain management.
Scilex’s commercial portfolio includes:
- ZTlido®: A lidocaine topical system approved for treating neuropathic pain.
- ELYXYB®: The first FDA-approved oral solution for acute migraine treatment.
- Gloperba®: The first oral liquid formulation of colchicine for gout prevention.
Future Product Developments
In addition to its existing products, Scilex has several promising candidates in development:
- SP-102: A novel viscous corticosteroid gel aimed at treating lumbosacral radicular pain.
- SP-103: An advanced lidocaine formulation for acute pain, recently completing Phase 2 trials.
- SP-104: A low-dose naltrexone being developed for fibromyalgia treatment.
Forward-Looking Statements
This announcement contains forward-looking statements that involve risks and uncertainties, including potential clinical developments related to SCLX's product candidates. These statements are not guarantees of future performance and actual results may differ significantly due to various factors such as market conditions, regulatory approvals, and operational capabilities.
Contact Information
For further inquiries about Scilex Holding Company, please visit www.scilexholding.com or connect through their social media channels: